SAS accelerates delivery of novel medicines using AI and analytics
Cooperation with AstraZeneca for more innovation in clinical research
Advertisement
SAS, a leader in AI and analytics, is helping to revolutionize the use of clinical trial data so new medicines can be delivered to patients faster than before. After a thorough evaluation, SAS has been chosen by global biopharmaceutical company AstraZeneca to help increase efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities, via SAS’s cloud-based software and technologies.
SAS will support the redesign of clinical and patient data flow by delivering industry-leading analytics and AI, manage changing trial designs in a fast-evolving regulatory environment, enable data re-use, and help accelerate reporting and submission timelines. It will also deliver increased capacity, automation, interoperability, and flexibility to bring in and analyze diverse and novel patient data sources – such as those coming from wearables, sensors and precision medicine – as part of the submissions process.
This will be achieved by supporting the analysis and reporting phases with SAS® Life Science Analytics Framework and SAS® Viya®, a scalable and powerful cloud-based industry platform enabling swift decision-making regardless of data volumes or complexity using modern cloud technologies. This has the potential to provide significant productivity gains by driving faster time to market and reduced IT costs. The SAS and AstraZeneca partnership will enable teams across the organization to collaborate and increase clinical research innovation.
Christopher J Miller, VP Biometrics at AstraZeneca, said, “This partnership with SAS supports the transformation of how we use clinical data to support our patient-centric approach and focus on getting medicines to patients faster than ever before. It will also allow us to introduce new ways of working and embrace new technologies and trial models to accelerate our portfolio.”
Bryan Harris, SAS Executive Vice President and Chief Technology Officer, said, “I’m delighted that SAS is building on the strong relationship it has had with AstraZeneca over many years by being part of this transformation program. The work they do positively impacts the lives of millions of people around the world.
“This is exciting because we have solidified a great foundation between our companies, but we also recognize we are just scratching the surface. We pay attention to technology and the advancements in AI, and we thrive on thinking through how our technology blended with AstraZeneca’s expertise and insight can create new medical solutions for their customers.”
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Gentle protein purification at the touch of a button - i3 Membrane revolutionizes the separation of biological agents
Bio-based plastics for infusion bags - Frankfurt research team develops sustainable alternative to medical products made from crude oil in cooperation with bioplastics start-up BIOVOX
Recipharm secures major additional grant to develop AI-enabled manufacturing technologies - Development of an AI-enabled simulator and process control platform, to speed up process development, cut costs and improve manufacturing efficiency
Merck Partners with Promega Corporation
Berlin is set to become a hotspot for the development of innovative therapies - More than just a ground-breaking ceremony: start of construction for the Berlin Center for Gene and Cell Therapies
Kerry Establishes New Biotechnology Centre in Leipzig - Centre to facilitate cutting-edge innovations with wide range of applications across food, beverage and pharma
Laboratory innovations and expert knowledge at analytica 2026 - Key topics: digitalization, automation, sustainability
BASF and IFF announce strategic collaboration to drive next-generation enzyme and polymer innovation
Smartbax secures 4.7 million euros in Pre-Series A funding for the further development of a novel antibiotic up to preclinical stage - Lead candidate against a novel target in Gram-negative bacteria has already been validated in infection models
FIRST LABS - Laboratory start-up support for start-ups - The Rock Capital Group is expanding its concept of ready-to-use laboratories in the life science hub at SKYGATE in Hallbergmoos, especially for start-ups and smaller companies
From beer to useful fats and medicines - The spent grain from beer brewing can be used to make microcapsules that can preserve omega-3 oils and medicines
